Jaguar Health, Inc. (NASDAQ:JAGX) Short Interest Update

by · The Cerbat Gem

Jaguar Health, Inc. (NASDAQ:JAGX – Get Free Report) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 413,000 shares, an increase of 11.4% from the September 15th total of 370,700 shares. Currently, 5.3% of the shares of the company are short sold. Based on an average daily volume of 717,100 shares, the short-interest ratio is presently 0.6 days.

Hedge Funds Weigh In On Jaguar Health

An institutional investor recently bought a new position in Jaguar Health stock. Perritt Capital Management Inc acquired a new position in shares of Jaguar Health, Inc. (NASDAQ:JAGX – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,000 shares of the biotechnology company’s stock, valued at approximately $90,000. Perritt Capital Management Inc owned 0.51% of Jaguar Health as of its most recent SEC filing. Institutional investors and hedge funds own 12.04% of the company’s stock.

Jaguar Health Stock Performance

Jaguar Health stock traded up $0.07 during midday trading on Wednesday, hitting $1.23. The company’s stock had a trading volume of 334,267 shares, compared to its average volume of 790,483. The company has a debt-to-equity ratio of 1.32, a current ratio of 2.10 and a quick ratio of 1.60. Jaguar Health has a 1-year low of $0.95 and a 1-year high of $30.86. The company has a 50-day moving average price of $1.17 and a two-hundred day moving average price of $4.71.

Jaguar Health (NASDAQ:JAGX – Get Free Report) last announced its earnings results on Tuesday, August 13th. The biotechnology company reported ($4.04) EPS for the quarter, missing the consensus estimate of ($1.20) by ($2.84). The business had revenue of $2.72 million for the quarter. Jaguar Health had a negative return on equity of 412.63% and a negative net margin of 350.18%. As a group, research analysts anticipate that Jaguar Health will post -0.78 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Jaguar Health from a “sell” rating to a “hold” rating in a research report on Friday, September 13th.

Read Our Latest Research Report on Jaguar Health

About Jaguar Health

(Get Free Report)

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.

Featured Stories